Natural Short-term Course of Recurrent Macular Edema Following Intravitreal Bevacizumab Therapy in Branch Retinal Vein Occlusion.
- Author:
Su Jin YOO
1
;
Jae Hui KIM
;
Tae Gon LEE
;
Jong Woo KIM
;
Sung Won CHO
;
Jung Il HAN
Author Information
- Publication Type:Original Article
- Keywords: Bevacizumab; Macular edema; Natural history; Recurrence; Retinal vein occlusion
- MeSH: Bevacizumab*; Curriculum*; Humans; Macular Edema*; Natural History; Observational Study; Recurrence; Retinal Vein Occlusion*; Retinal Vein*; Retinaldehyde*; Retrospective Studies; Visual Acuity
- From:Korean Journal of Ophthalmology 2017;31(2):95-101
- CountryRepublic of Korea
- Language:English
- Abstract: PURPOSE: To evaluate the 3-month natural course of recurrent macular edema secondary to branch retinal vein occlusion (BRVO) treated with intravitreal bevacizumab. METHODS: This retrospective, observational study included 36 eyes with macular edema secondary to BRVO. All patients were initially treated with intravitreal bevacizumab for macular edema. Recurrence of macular edema was either not treated (untreated group) or treated with a single intravitreal bevacizumab injection (treated group). Central foveal thickness (CFT) and best-corrected visual acuity (BCVA) were compared at the time of recurrence and 3 months later. RESULTS: At the time of recurrence, the mean CFT and logarithm of the minimum angle of resolution BCVA were 484.9 ± 124.1 µm and 0.58 ± 0.26 in the untreated group (n = 19) and 456.3 ± 126.8 µm and 0.51 ± 0.21 in the treated group (n = 17), respectively. Three months later, the mean CFT and BCVA had changed to 493.7 ± 123.9 µm and 0.62 ± 0.29 in the untreated group and 294.7 ± 104.4 µm and 0.40 ± 0.24 in the treated group, respectively. The differences in CFT and BCVA between the two time points were not significant in the untreated group (p = 0.106 and p = 0.687, respectively), whereas statistically significant differences were noted in the treated group (p = 0.002 and p < 0.001, respectively). CONCLUSIONS: Unlike the first episode of macular edema following BRVO, recurrent macular edema following intravitreal bevacizumab therapy did not spontaneously resolve, suggesting the potential benefit of prompt treatment.
